 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Humasis announced on the 21st that it has submitted a creditor objection to the merger between Celltrion and Celltrion Healthcare.
Humasis, which is suing Celltrion for a contract to supply the COVID-19 diagnostic kit, insisted that Celltrion "execute due process, such as repayment or provision of collateral, as a debtor."
Celltrion decided to merge with Celltrion Healthcare through an extraordinary shareholders' meeting on the 23rd of last month. The merger of the two companies was passed at each company's extraordinary shareholders' meeting.
"We will conduct an internal review of the contents received during the submission period so that there will be no problems with the merger process," a Celltrion official said.
Celltrion and Humasis jointly developed kits through a contract to develop and supply COVID-19 diagnostic kits in June 2020 and began delivering them to the U.S. market through Celltrion's U.S. subsidiary, but clashed over supply shortages.
Celltrion claimed that Humasis degraded its reputation by failing to supply its products at a time when demand for diagnostic kits in the U.S. soared, while Humasis countered that Celltrion demanded excessive unit price cuts and subsidies, and filed a lawsuit against each other for damages ranging between 60 billion won and 70 billion won, respectively.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
